Abstract 2501
Background
MET addicted tumors are known to show very short response to single MET inhibition. In MET addicted cells, MET inhibition leads to activation of proviral integration site for Moloney murine leukemia virus-1 (PIM1). PIM1 and SRC can regulate the expression of receptor tyrosine kinases (RTKs), potentially being responsible of resistance to MET inhibition. We previously showed that the dual inhibition of MET and PIM1 with class I MET inhibitors and the pan-PIM inhibitor AZD1208, as well as MET and SRC (with dasatinib), is synergistic in MET addicted cell lines.
Methods
We evaluated the activity of class I and class II MET inhibitors, MET/SRC/CSF1R inhibitor TPX-02226 and pan-PIM inhibitors AZD1208 and PIM447 in four MET addicted cell lines: 2 MET amplified lung cancer cell lines (EBC1 and H1993), 1 MET exon 14 mutant cell line (Hs746T) and 1 MET exon 7-8 splicing variant cell line (E98). We assessed the effect of the dual inhibition of MET and PIM, and the triple inhibition of MET, SRC and PIM in cell viability by combining the TPX-02226 with the pan-PIM inhibitors.
Results
All cell lines were sensitive to class I-II MET inhibitors (IC50s in nM range) except for cabozantinib in H1993. Only the MET amplified cell lines were sensitive to TPX-02226. All cell lines were resistant to PIM inhibition. The combination of class I MET inhibitors with PIM447 showed stronger synergism in the MET amplified cell lines, compared to the combination with AZD1208. Class I-II MET inhibitors and PIM inhibitor combination showed only additive effect in exon 7-8 cell line E98, while the combination of TPX-02226 and PIM447 was strongly synergistic.
Conclusions
We identified potential role of PIM inhibition in MET amplified tumors. Even though single agent TPX-02226, AZD1208 or PIM447 showed no activity and dual MET/PIM inhibition showed only additive effect, the triple inhibition of MET, SRC and PIM was strongly effective in MET exon 7-8 splicing variant, suggesting a crucial role of SRC-PIM interaction in this still not well recognized MET addicted tumor. Further investigation on this triple inhibition is ongoing in MET addicted cell lines and role of co-presence of MET and PIM1 and/or SRC alterations in tumor samples.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IGTP, Germans Trias i Pujol Research Institute, Badalona, Barcelona, Spain.
Funding
Fundació Obra Social “La Caixa”.
Disclosure
J.J. Cui: Leadership role, Officer / Board of Directors: TP Therapeutics. N. Karachaliou: Officer / Board of Directors: Merck KgaA. All other authors have declared no conflicts of interest.
Resources from the same session
2963 - Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib
Presenter: Ira Pekker
Session: Poster Display session 3
Resources:
Abstract
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract